Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 4/20 | 0.64 |
| ▸ | MEF2D | Q14814 | 4/20 | 0.64 |
| ▸ | EP300 | Q09472 | 3/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.51 |
| ▸ | F7 | P08709 | 2/20 | 0.51 |
| ▸ | F3 | P13726 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091462 | 1.00 | HDAC4 (0.64) | HDAC4MEF2DEP300HDAC1F7 | |
| SCHEMBL3095378 | 0.90 | HDAC4 (0.60) | HDAC4MEF2DEP300HDAC1F7 | |
| SCHEMBL3095363 | 0.90 | HDAC4 (0.60) | HDAC4MEF2DEP300HDAC1F7 | |
| SCHEMBL3102684 | 0.88 | HDAC4 (0.56) | HDAC4MEF2DEP300HDAC1HDAC3 | |
| SCHEMBL3102699 | 0.88 | HDAC4 (0.56) | HDAC4MEF2DEP300HDAC1HDAC3 | |
| SCHEMBL3098713 | 0.87 | HDAC4 (0.58) | HDAC4MEF2DEP300HDAC1HDAC3 | |
| SCHEMBL3098720 | 0.87 | HDAC4 (0.58) | HDAC4MEF2DEP300HDAC1HDAC3 | |
| SCHEMBL3099532 | 0.86 | HDAC4 (0.55) | HDAC4MEF2DEP300HDAC1HDAC3 | |
| SCHEMBL3099517 | 0.86 | HDAC4 (0.55) | HDAC4MEF2DEP300HDAC1HDAC3 | |
| SCHEMBL8029197 | 0.86 | HDAC4 (0.57) | HDAC4MEF2DEP300HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795315-B2 | N-(2-amino-phenyl)-amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795315-B2 | N-(2-amino-phenyl)-amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795315-B2 | N-(2-amino-phenyl)-amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | MKI67, API5, BAD | HDAC4 1003/4885MEF2D 923/4885EP300 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.